WFRF:(Hagberg Oskar)
Sökning: WFRF:(Hagberg Oskar) > Adjuvant chemothera...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 06821naa a2200769 4500 | |
| 001 | oai:DiVA.org:uu-360179 | |
| 003 | SwePub | |
| 008 | 180913s2018 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:138664185 | |
| 009 | oai:DiVA.org:liu-149842 | |
| 009 | oai:lup.lub.lu.se:4c4eb951-eb77-4b3d-8e13-d9173093a3d0 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3601792 URI |
| 024 | 7 | a https://doi.org/10.1016/j.ejca.2018.05.0112 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1386641852 URI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1498422 URI |
| 024 | 7 | a https://lup.lub.lu.se/record/4c4eb951-eb77-4b3d-8e13-d9173093a3d02 URI |
| 040 | a (SwePub)uud (SwePub)kid (SwePub)liud (SwePub)lu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Hall, Kirsten Sundbyu Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway,Oslo university hospital,Norwegian Radium Hospital4 aut |
| 245 | 1 0 | a Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX) |
| 264 | 1 | b ELSEVIER SCI LTD,c 2018 |
| 338 | a print2 rdacarrier | |
| 500 | a Funding Agencies|Swedish Cancer Society; National Advisory Unit for Sarcoma in Norway | |
| 520 | a Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy.Methods: High-risk STS was defined as high-grade morphology (according to the Federation Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II-III) and either vascular invasion or at least two of the following criteria: tumour size >= 8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m(2)) and ifosfamide (6 g/m(2)) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4.Results: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2-8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1-78.4) with a local recurrence rate of 14.0% (95% CI: 7.8-20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2-8.7). The five-year OS was 76.1% (95% CI: 68.8-84.2). Tumour size, deep location and reduced dose intensity (<80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death.Conclusions: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a Soft tissue sarcoma | |
| 653 | a Adjuvant treatment | |
| 653 | a Prognostic factors | |
| 653 | a Vascular invasion | |
| 653 | a Growth pattern | |
| 653 | a Tumour size | |
| 653 | a Necrosis | |
| 653 | a Survival | |
| 653 | a Adjuvant treatment | |
| 653 | a Growth pattern | |
| 653 | a Necrosis | |
| 653 | a Prognostic factors | |
| 653 | a Soft tissue sarcoma | |
| 653 | a Survival | |
| 653 | a Tumour size | |
| 653 | a Vascular invasion | |
| 700 | 1 | a Bruland, Oyvind S.u Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway;Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway,Oslo university hospital,Norwegian Radium Hospital,University of Oslo4 aut |
| 700 | 1 | a Bjerkehagen, Bodilu Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway,Norwegian Radium Hospital,Oslo university hospital4 aut |
| 700 | 1 | a Zaikova, Olgau Oslo Univ Hosp, Div Orthopaed Surg, Oslo, Norway,Oslo university hospital4 aut |
| 700 | 1 | a Engellau, Jacobu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)onk-jen |
| 700 | 1 | a Hagberg, Oskaru Reg Canc Ctr South, Lund, Sweden,Skåne University Hospital4 aut0 (Swepub:lu)mats-oha |
| 700 | 1 | a Hansson, Linau Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden,Sahlgrenska University Hospital4 aut |
| 700 | 1 | a Hagberg, Hansu Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Uppsala Univ Hosp, Sweden,Uppsala University Hospital4 aut0 (Swepub:uu)hanshagb |
| 700 | 1 | a Ahlstrom, Marieu Lund Univ, Lund, Sweden;Skane Univ Hosp, Dept Oncol, Lund, Sweden,Lund University,Skåne University Hospital4 aut |
| 700 | 1 | a Knobel, Heidiu St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway,St. Olav’s University Hospital4 aut |
| 700 | 1 | a Papworth, Karinu Norrlands Univ Hosp, Dept Oncol, Umea, Sweden,Norrland University Hospital4 aut |
| 700 | 1 | a Zemmler, Majau Linkoping Univ Hosp, Dept Oncol, Linkoping, Sweden,Region Östergötland, Onkologiska kliniken US,Linköping University Hospital4 aut0 (Swepub:liu)n/a |
| 700 | 1 | a Goplen, Dorotau Haukeland Hosp, Dept Musculoskeletal Tumour Serv Oncol, Bergen, Norway,Haukeland University Hospital4 aut |
| 700 | 1 | a Bauer, Henrik C. F.u Karolinska Institute4 aut |
| 700 | 1 | a Eriksson, Mikaelu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)onk-mer |
| 710 | 2 | a Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norwayb Oslo university hospital4 org |
| 773 | 0 | t European Journal of Cancerd : ELSEVIER SCI LTDg 99, s. 78-85q 99<78-85x 0959-8049x 1879-0852 |
| 856 | 4 | u http://dx.doi.org/10.1016/j.ejca.2018.05.011y FULLTEXT |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-360179 |
| 856 | 4 8 | u https://doi.org/10.1016/j.ejca.2018.05.011 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:138664185 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-149842 |
| 856 | 4 8 | u https://lup.lub.lu.se/record/4c4eb951-eb77-4b3d-8e13-d9173093a3d0 |
Hitta via bibliotek
- European Journal of Cancer (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Hall, Kirsten Su ...
- Bruland, Oyvind ...
- Bjerkehagen, Bod ...
- Zaikova, Olga
- Engellau, Jacob
- Hagberg, Oskar
- visa fler...
- Hansson, Lina
- Hagberg, Hans
- Ahlstrom, Marie
- Knobel, Heidi
- Papworth, Karin
- Zemmler, Maja
- Goplen, Dorota
- Bauer, Henrik C. ...
- Eriksson, Mikael
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- European Journal ...
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
